StreetAlpha.app
Home › Stocks › MIRM

Mirum Pharmaceuticals, Inc. (MIRM)

Healthcare
$96.13
▲ +0.65%
LAST CLOSE · NOV 20

Mirum develops and sells medicines for rare liver and other rare diseases, based in Foster City, California. It last closed at $96.13 on Nov 20, up 0.65% on the day. The next earnings report for MIRM is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, MIRM reported EPS of -$0.87 on revenue of $185.7M, with revenue up 39.6% from a year ago. Over its last 8 reports the stock moved an average of 8.8% the session after earnings. Over the last 12 months MIRM insiders bought $9.0M of stock on the open market and sold $45.5M, according to SEC Form 4 filings.

AI Auto Pilots
Is MIRM in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold MIRM.

Key Stats

Last 12 months
Results
Revenue
$670.8M
+42.2% vs a year ago
Net income
−$903.9M
−134.8% margin
EPS (diluted)
−$14.47
Free cash flow
−$273.9M
−40.8% margin
Valuation
Market cap
$6.3B
65.3M shares
P/E
–
No P/E while losing money
Price to sales
9.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$243.2M
At Sep 30
Debt
$731.3M
At Sep 30
Shareholder equity
−$54.2M
Shares outstanding
65.3M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $19.1M$19.1MFY2021FY2022: $77.1M$77.1MFY2022FY2023: $186.4M$186.4MFY2023FY2024: $336.9M$336.9MFY2024FY2025: $521.3M$521.3MFY2025

From MIRM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$0.87
Quarter ended Sep 2026
Year ago EPS
$0.05
−1840.0% on a GAAP basis
Revenue
$185.7M
+39.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.49Dec '24Mar 2025: -$0.30Mar '25Jun 2025: -$0.12Jun '25Sep 2025: $0.05Sep '25Dec 2025: -$0.12Dec '25Mar 2026: -$13.43Mar '26Jun 2026: -$1.06Jun '26Sep 2026: -$0.87Sep '26Latest -$0.87
Revenue by quarter
Dec 2024: $99.4MDec '24Mar 2025: $111.6MMar '25Jun 2025: $127.8MJun '25Sep 2025: $133.0MSep '25Dec 2025: $148.9MDec '25Mar 2026: $159.9MMar '26Jun 2026: $176.2MJun '26Sep 2026: $185.7MSep '26Latest $185.7M
How MIRM moved after its last 8 reports
Average move the session after a report ±8.8%
Nov 3, 2026After the close+11.4%
Aug 5, 2026After the close−11.0%
May 6, 2026After the close−6.5%
Feb 25, 2026After the close−15.1%
Jan 12, 2026Time not announced+3.4%
Nov 4, 2025After the close−1.2%
Aug 6, 2025After the close+12.0%
May 7, 2025After the close+9.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on MIRMStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on MIRM
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on MIRM

Technical Analysis

MIRM · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend, nearing overbought

The stock is 5% above its 20 day and 8% above its 50 day average. It is 2% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 63), near overbought. The nearest support is the swing low (Aug 25) at $95.00, and the nearest resistance the Pivot at $96.21.

Short trendBullish
Long trendBearish
MomentumStrong
StretchNear overbought
VolatilityNormal, 4.0%/day
Key levels
$130.0052 week high+35.2%
$98.97Swing high (Nov 5)+3.0%
$98.31Pivot R1+2.3%
$98.17200 day average+2.1%
$97.75100 day average+1.7%
$96.21Pivot+0.1%
$96.13Last close
$95.00Swing low (Aug 25)−1.2%
$94.02Pivot S1−2.2%
$91.0120 day average−5.3%
$88.1950 day average−8.3%
$63.2352 week low−34.2%
Indicators
RSI (14)62.53Strong, overbought above 70Neutral
MACD2.09Above its signal lineBullish
Stochastic73.1Middle of its rangeNeutral
ADX (14)24.8Weak trend
Williams %R-17.9Oversold below −80, overbought above −20Overbought
CCI (20)99.0Oversold below −100, overbought above 100Neutral
Rate of change+2.6%Change over 10 sessionsBullish
ATR (14)$3.80Typical daily range, 4.0% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for MIRM

What happened before

See how MIRM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow MIRM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How MIRM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for MIRMHow many large options trades hit MIRM, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

MIRM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●173 buying vs 152 selling
  • ▲Held by funds +0.8 pts
  • ▼Funds holding -11
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding320331−3.3%
In funds' top 101020−50.0%
Held by funds110.3%109.6%+0.8 pts
New / increased49 / 12459 / 126−6.5%
Reduced / sold out96 / 56102 / 45+3.4%
Put/call ratio0.453.30−86.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MIRM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

MIRM Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$9.0M1 buy · 1 insider
Sold$45.5M45 sales · 8 insiders
60% of the selling was under pre-arranged trading plans.
2025-12 sold $8.1M2026-01 bought $9.0M2026-01 sold $3.2M2026-02 sold $1.5M2026-03 sold $7.2M2026-04 sold $194K2026-05 sold $219K2026-06 sold $4.0M2026-07 sold $3.4M2026-08 sold $6.8M2026-09 sold $4.0M2026-11 sold $3.3MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Saira RamasastryDirectorSale plan2,000$92.28$185K
Nov 11Laura BregeDirectorSale14,167$94.21$1.3M
Nov 4Christopher PeetzCEOSale plan20,000$90.00$1.8M
Sep 14Eric BjerkholtCFOSale9,943$98.37$978K
Sep 2Jolanda HoweSvp, Global ControllerSale plan658$100.00$66K
Sep 1Christopher PeetzCEOSale plan30,000$98.68$3.0M
Every insider buy and sale for MIRM over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See MIRM insider trades →

From SEC Form 4 filings by MIRM's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MIRM is in one of them and how their past MIRM trades turned out.

MIRM in the AI portfolios
Loading…

MIRM News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MIRM in an article yet. Here's the latest on the wider market.

MIRM in the news

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a biopharmaceutical company based in Foster City, California, that develops and sells medicines for rare diseases, mainly rare liver conditions. Its approved products are Livmarli, used to treat severe itching in certain rare cholestatic liver diseases, and Cholbam and Ctexli, used for bile acid disorders and a rare brain and tendon condition. It sells these medicines mainly in the United States and through partners in other countries, and it is developing treatments for other rare liver diseases and a rare genetic neurological disorder. Its customers include patients, physicians and specialty pharmacies.

Headquarters
Foster City, CA
Founded
2018